Pathstone Holdings
MGX icon

Pathstone Holdings’s Metagenomi Therapeutics MGX Stock Holding History

Pathstone Holdings’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,648
Closed -$18.6K – 2352
2025
Q1 		$18.6K Hold
13,648
– – ﹤0.01% 2208
2024
Q4 		$49.3K Sell
13,648
-7,000
-34% -$16.9K ﹤0.01% 2267
2024
Q3 		$44.8K Buy
+20,648
New +$71.6K ﹤0.01% 2299

Other funds holding MGX

SVGI
Sozo Ventures GP II Redwood City, California $1.33B AUM 9.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pathstone Holdings's MGX Position: Q2 2025 in Review

Pathstone Holdings sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 13,648 shares — an estimated $18.6K sold.

Pathstone Holdings first reported a position in MGX in Q3 2024 and held it in 3 quarters. The position peaked at $49.3K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Pathstone Holdings reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Pathstone Holdings sold 13,648 Metagenomi Therapeutics shares in Q2 2025, an estimated $18.6K.
  • Pathstone Holdings first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 3 quarters.
  • Pathstone Holdings's Metagenomi Therapeutics position peaked at $49.3K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Pathstone Holdings's 13F filing for Q2 2025, filed 12 Aug 2025.